MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets

MYC通过干扰雄激素受体靶点的转录暂停释放,驱动侵袭性前列腺癌的发生。

阅读:5
作者:Xintao Qiu # ,Nadia Boufaied # ,Tarek Hallal ,Avery Feit ,Anna de Polo ,Adrienne M Luoma ,Walaa Alahmadi ,Janie Larocque ,Giorgia Zadra ,Yingtian Xie ,Shengqing Gu ,Qin Tang ,Yi Zhang ,Sudeepa Syamala ,Ji-Heui Seo ,Connor Bell ,Edward O'Connor ,Yang Liu ,Edward M Schaeffer ,R Jeffrey Karnes ,Sheila Weinmann ,Elai Davicioni ,Colm Morrissey ,Paloma Cejas ,Leigh Ellis ,Massimo Loda ,Kai W Wucherpfennig ,Mark M Pomerantz ,Daniel E Spratt ,Eva Corey ,Matthew L Freedman ,X Shirley Liu ,Myles Brown ,Henry W Long ,David P Labbé

Abstract

c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression. Although MYC is overexpressed in both early and metastatic disease and associated with poor survival, its impact on prostate transcriptional reprogramming remains elusive. We demonstrate that MYC overexpression significantly diminishes the androgen receptor (AR) transcriptional program (the set of genes directly targeted by the AR protein) in luminal prostate cells without altering AR expression. Analyses of clinical specimens reveal that concurrent low AR and high MYC transcriptional programs accelerate prostate cancer progression toward a metastatic, castration-resistant disease. Data integration of single-cell transcriptomics together with ChIP-seq uncover an increase in RNA polymerase II (Pol II) promoter-proximal pausing at AR-dependent genes following MYC overexpression without an accompanying deactivation of AR-bound enhancers. Altogether, our findings suggest that MYC overexpression antagonizes the canonical AR transcriptional program and contributes to prostate tumor initiation and progression by disrupting transcriptional pause release at AR-regulated genes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。